-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 23, Chuangxiang Bio announced that the Center for Drug Evaluation (CDE) of the State Drug Administration has officially accepted the IND application of its candidate drug izokibep (IMG-020) for the treatment of plaque psoriasis.
Izokibep is jointly developed by Chuangxiang and its partners Sweden Affibody AB (hereinafter referred to as "Affibody") and American ACELYRIN, INC.
Chuangxiang is responsible for leading and organizing the design, submission and development of global clinical studies for indications such as psoriasis, ankylosing spondylitis and Takayasu arteritis
Note: The original text has been deleted